Roche licenses Alector Parkinson's therapy in $1.27B deal
Roche committed $100 million upfront to license Alector's experimental Parkinson's program in a deal potentially worth $1.27 billion.
Palanor Wire · composed from 3 outlets · every claim links to its sources
What happened
Roche licensed Alector's experimental Parkinson's program through Genentech. 12 Roche committed $100 million upfront in the deal. 12 The agreement is potentially worth up to $1.27 billion. 13 Alector's stock price soared on the news. 3
Why it matters
The deal centers on Alector's neuroscience and Parkinson's disease efforts. 2 Alector recently had a separate partnership collapse. 2
Sources · 3
[1]Roche Stocks: Genentech Commits $100 Million Upfront in Potential $1.27 Billion Parkinson's Deal
gurufocus.com · via Marketaux
[2]Roche enlists Alector in Parkinson's deal, paying $100M upfront
Endpoints News
[3]Alector soars as Roche licenses Parkinson's therapy for up to $1.27 billion reut.rs/4yrJTiF
Reuters · Bluesky
Matched signals
Lattice signals Numen pinned to this story at publish time.
No matched signals on this story.
Unlock the analytical widgets on every article — signal matches, Trends snapshots, X overlays, agent reasoning — with a Member account.
Upgrade →On X right now
Top engagement posts about this topic, ranked by likes + retweets + quotes.
No high-engagement X posts captured for this topic. Either the topic is too quiet or the upstream API was unavailable when this article published.
Unlock the analytical widgets on every article — signal matches, Trends snapshots, X overlays, agent reasoning — with a Member account.
Upgrade →Your read
How did this article land?
Three sliders. Optional comment. Anonymous is fine.
Open to anyone. One response per reader.